Literature DB >> 18632004

Differentiating Alzheimer's disease from dementia with Lewy bodies and Parkinson's disease with (+)-[11C]dihydrotetrabenazine positron emission tomography.

Robert A Koeppe1, Sid Gilman, Larry Junck, Kris Wernette, Kirk A Frey.   

Abstract

BACKGROUND: Several progressive neurologic disorders begin with cognitive decline or parkinsonism, notably Alzheimer's disease (AD), Parkinson's disease (PD), and dementia with Lewy bodies (DLB). We used positron emission tomography (PET) in attempts to differentiate these disorders.
METHODS: We performed PET with (+)-[11C]dihydrotetrabenazine ([11C]DTBZ) to examine blood-to-brain ligand transport (K(1)) and striatal monoaminergic presynaptic binding (distribution volume [DV]) in 25 DLB, 30 PD, and 25 AD patients and 57 elderly controls (NC).
RESULTS: [11C]DTBZ DV was decreased significantly in caudate nucleus, anterior putamen, and posterior putamen in DLB and PD compared with AD and NC. DLB and PD groups showed an anterior-to-posterior gradient of binding loss relative to NC, least in caudate nucleus and largest in posterior putamen. The gradient was significantly steeper in PD than DLB. Both PD and DLB showed significantly greater interhemispheric striatal binding asymmetry than NC, and PD had greater asymmetry than DLB. Cerebral cortical [11C]DTBZ K(1) was decreased diffusely by 4% to 8% in PD. Larger K(1) deficits occurred in AD and DLB temporoparietal and prefrontal association cortices and posterior cingulate cortex. Greater reduction of K(1) occurred in occipital cortex in DLB than AD. Receiver operating characteristic curve analyses distinguished DLB from AD more effectively on the basis of striatal DV than occipital K(1) and distinguished DLB from PD more effectively on the basis of cerebral cortical K(1) than striatal DV patterns. Overall, 90% of cases were properly classified by combining these measures.
CONCLUSIONS: PET with [11C]DTBZ can differentiate DLB from both PD and AD in a single neuroimaging study.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632004     DOI: 10.1016/j.jalz.2007.11.016

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  16 in total

Review 1.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Kirk A Frey
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-14       Impact factor: 5.081

3.  Imaging Amyloidopathy in Parkinson Disease and Parkinsonian Dementia Syndromes.

Authors:  Kirk A Frey; Myria Petrou
Journal:  Clin Transl Imaging       Date:  2015-02-01

Review 4.  Lewy Body Disease: Clinical and Pathological "Overlap Syndrome" Between Synucleinopathies (Parkinson Disease) and Tauopathies (Alzheimer Disease).

Authors:  Clovis Foguem; Patrick Manckoundia
Journal:  Curr Neurol Neurosci Rep       Date:  2018-04-08       Impact factor: 5.081

5.  Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.

Authors:  James F Burke; Roger L Albin; Robert A Koeppe; Bruno Giordani; Michael R Kilbourn; Sid Gilman; Kirk A Frey
Journal:  Brain       Date:  2011-05-09       Impact factor: 13.501

6.  UPDATE ON DEMENTIA WITH LEWY BODIES.

Authors:  Stella Karantzoulis; James E Galvin
Journal:  Curr Transl Geriatr Exp Gerontol Rep       Date:  2013-09-01

Review 7.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

8.  PET quantification of pancreatic VMAT 2 binding using (+) and (-) enantiomers of [¹⁸F]FP-DTBZ in baboons.

Authors:  Paul E Harris; Michael D Farwell; Masanori Ichise
Journal:  Nucl Med Biol       Date:  2012-10-26       Impact factor: 2.408

9.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

10.  Structural and functional imaging in parkinsonian syndromes.

Authors:  Stephen M Broski; Christopher H Hunt; Geoffrey B Johnson; Robert F Morreale; Val J Lowe; Patrick J Peller
Journal:  Radiographics       Date:  2014 Sep-Oct       Impact factor: 5.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.